Cormedix Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012. The filing is an annual report, not a standalone Q4 report; quarterly financial results are not clearly provided in the supplied text.
Business context
CorMedix is a development-stage pharmaceutical and medical device company with no product sales. Its main focus is CRMD003 (Neutrolin), a catheter-lock solution intended to prevent catheter-related bloodstream infections and maintain catheter patency, initially in hemodialysis patients. CRMD004, a gel formulation, remained preclinical and was deferred. The company discontinued CRMD001 development in 2011.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.19 million | $4.10 million |
| General and administrative expense | $1.86 million | $3.15 million |
| Total operating expenses / operating loss | $3.04 million | $7.25 million |
| Net loss | $3.43 million; $0.30 per share | $6.71 million; $0.59 per share |
| Operating cash used | $2.28 million | $6.30 million |
| Cash and cash equivalents at year-end | $835,471 | $1.99 million |
There is no meaningful product gross margin to report because the company had no product revenue. FY2012 net loss improved by about 49% year over year, mainly reflecting lower R&D and G&A spending; the company also reported $382,936 of interest expense in 2012 versus none in 2011.
At December 31, 2012, current assets were $1.14 million and current liabilities were $1.62 million, implying a current ratio of approximately 0.70. Total liabilities were $1.63 million, and stockholders’ equity was negative $475,376. The 9% senior convertible notes had $1.324 million aggregate principal, due in September and November 2013; their balance-sheet carrying value was reduced by debt discounts. The company reported no cash interest paid in 2012.
CorMedix raised $1.324 million gross ($1.096 million net) through 2012 convertible-note placements and raised a further $533,000 gross in a February 2013 preferred-stock financing. Management said available funds were expected to cover operations only into the second quarter of 2013. The auditor expressed substantial doubt about the company’s ability to continue as a going concern.
Material changes versus the prior year
- R&D expense fell $2.91 million and G&A expense fell $1.29 million, reflecting the strategic focus on European Neutrolin approval, discontinuation of CRMD001, and lower personnel and other costs.
- Operating cash use decreased by about $4.02 million, while year-end cash fell by $1.15 million to $835,471.
- The company issued convertible debt in 2012, creating 2013 maturities and potential dilution through conversion and warrants.
- Stockholders’ equity moved from positive $1.24 million to a deficit of $475,376.
Outlook, risks, and unusual items
- CorMedix anticipated CE Mark approval for Neutrolin in Q2 2013 and planned an initial European launch in Germany during 2013. After year-end, the Dutch Medicinal Evaluation Board gave a positive response on the clinical aspect of the application; final packaging and remaining review were still pending. Approval and launch timing were not assured.
- For U.S. approval, management expected to resume FDA discussions after European approval. The anticipated pathway could require a pivotal Phase III trial and possibly an additional Phase IIb trial; the filing projected a program beginning in 2014 and potential approval in 2016, subject to regulatory requirements and funding.
- The company had no employees as of March 1, 2013 and relied on consultants and outsourced manufacturing. Its commercialization plans depended on financing, regulatory approval, third-party manufacturing, distribution, and reimbursement.
- Management disclosed a material weakness in financial reporting controls relating to expertise in complex accounting. Controls were deemed ineffective at December 31, 2012; the weakness had not affected 2012 statements but had led to a restatement of the September 2012 quarterly report. A remediation process was initiated in 2013.
- NYSE MKT had extended the company’s compliance-plan period to April 15, 2013; failure to regain listing compliance could lead to delisting. A European patent appeal verbally upheld a key Neutrolin patent but remanded the matter for possible claim restrictions; a written decision was pending.
- The 2012 notes and warrants, February 2013 preferred shares and warrant, and other outstanding options and warrants create substantial potential dilution. The company also disclosed registration-related liquidated damages of $8,750 per month, subject to a $43,750 cap, while a resale registration statement remained ineffective.
Key facts for investors to verify
- Current cash, operating burn, and financing needs relative to the stated Q2 2013 runway.
- Final CE Mark decision, remaining packaging or regulatory requirements, and the feasibility and cost of a European launch.
- Terms, maturities, conversion, and potential dilution from the 2012 notes and warrants and the 2013 preferred financing.
- Progress in remediating the material weakness and the status of NYSE MKT listing compliance.
- Outcome of the patent appeal and any effect of claim restrictions on Neutrolin’s protection.